Johnson & Johnson (J&J) has finalized its acquisition of Halda Therapeutics OpCo, Inc. for $3.05 billion, aiming to bolster its Innovative Medicine segment. Anticipating accelerated growth by 2026, J&J's robust financial position is underscored by its S&P Global ‘AAA’ credit rating and a dividend yield of 2.50%, supported by over six decades of increases. Despite expectations of earnings dilution in late 2025, analysts suggest that J&J is well-positioned to outperform the broader market.
“Johnson & Johnson · has completed the acquisition of Halda Therapeutics OpCo, Inc. · $3.05 billion in cash · 3.05 billion”
“Johnson & Johnson · expects · accelerated growth · in the Innovative Medicine segment in 2026”
“Johnson & Johnson (JNJ) · returned · percentage · 14.3%”
“Johnson & Johnson · maintains · S&P Global’s top-tier ‘AAA’ credit rating · true”
“Johnson & Johnson · has · current dividend of $5.20 per share · true”
“Johnson & Johnson · offers · dividend yield of 2.50% · true”
“Johnson & Johnson · is a member of · S&P Dividend Aristocrats · true”
“J&J · makes · drugs and medical devices · true”
“Johnson & Johnson · has · the lowest dividend yield · 2.5%”
“Johnson & Johnson · has · over six decades of dividend increases · true”
“Johnson & Johnson · currently has an average brokerage recommendation · ABR · 1.85”
“Johnson & Johnson · received approval from the U.S. Food and Drug Administration (FDA) for · RYBREVANT FASPRO · true”
